Dutch Biotech Secures €1.3 Million to Make Arthritis Drug Work Better
Netherlands, Wednesday, 4 March 2026.
Amplio Pharma’s breakthrough approach doesn’t create new drugs but makes existing ones more effective by adding novobiocin as a cellular gatekeeper that prevents methotrexate from being pumped out of inflamed cells too quickly. This innovative delivery system could allow patients to use lower doses with fewer side effects while delaying expensive biological treatments that cost healthcare systems significantly more than standard therapy.
Understanding the Medical Innovation
This development represents a significant advancement in healthtech, specifically targeting autoimmune disease treatment through innovative drug delivery systems [1]. Rheumatoid arthritis affects millions worldwide as a chronic autoimmune condition that causes joint inflammation and pain [GPT]. The core challenge that Amplio Pharma addresses lies in methotrexate’s current limitations - while it stands as the most prescribed basic medication against rheumatoid arthritis globally, the drug gets expelled from cells and tissues too quickly to achieve optimal effectiveness [1].
How NovoBioJect Technology Works
The Dutch company’s NovoBioJect system employs a sophisticated cellular mechanism to enhance methotrexate’s therapeutic impact [1]. The technology adds novobiocin, which functions as a gatekeeper that temporarily slows down the efflux pump in cells - essentially the cellular ‘doorways’ through which methotrexate normally gets pumped back out [1]. This intervention allows methotrexate to remain longer in inflamed cells, enabling the medication to perform its therapeutic work more powerfully [1]. The enhanced effectiveness means methotrexate can be prescribed at lower dosages while working successfully in a larger patient population [1].
Clinical Progress and Investment Utilization
Amplio Pharma has successfully completed essential preclinical studies and currently operates a Phase 1b clinical study with rheumatoid arthritis patients [1]. Following an interim analysis, initial results appear promising [1]. The €1.3 million investment will finance the company’s ongoing clinical research with NovoBioJect, supporting both the current Phase 1b study and preparation of the Clinical Trial Application for the next, larger-scale patient study [1]. The funding round included participation from ROM InWest, Libertatis Ergo Holding B.V., Amsterdam Academic Ventures, and Innovatiefonds Noord-Holland [2].
Company Leadership and Location
Amplio Pharma operates as a Dutch biotech company that leverages Amsterdam’s strong knowledge base around Amsterdam UMC [1]. The company collaborates closely with the Leiden ecosystem to accelerate early clinical development [1]. ROM InWest’s investment decision aligns with their focus on supporting North Holland Life Sciences & Health enterprises that demonstrate clear social impact [1]. The technology extends beyond rheumatoid arthritis, targeting immune-mediated inflammatory diseases with potential applications for conditions including psoriasis and Crohn’s disease [1].